Showing results (61-70 of 105) with videos related to
Sort By:
Pageof 11
Frontiers in Immunology|May 2, 2022
A Phase 1 Dose-Escalation Study of PF-06671008, a Bispecific T-Cell-Engaging Therapy Targeting P-Cadherin in Patients With Advanced Solid TumorsJames J Harding, Ignacio Garrido-Laguna, Xiaoying Chen, et al.Organic & Biomolecular Chemistry|December 17, 2008
New scaffolds for the design of selective estrogen receptor modulatorsSonsoles Martín-Santamaría, José-Juan Rodríguez, Sonia de Pascual-Teresa, et al.The Oncologist|September 26, 2022
Epacadostat Plus Pembrolizumab and Chemotherapy for Advanced Solid Tumors: Results from the Phase I/II ECHO-207/KEYNOTE-723 StudyJohn D Powderly, Samuel J Klempner, Aung Naing, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2023
Treatment Response in First-Line Metastatic Pancreatic Ductal Adenocarcinoma Is Stratified By a Composite Index of Tumor Proliferation and CD8 T-Cell InfiltrationGregory L Beatty, Devora Delman, Jiayi Yu, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 2, 2023
Comparative Genomic Analysis of Pancreatic Acinar Cell Carcinoma (PACC) and Pancreatic Ductal Adenocarcinoma (PDAC) Unveils New Actionable Genomic Aberrations in PACCVaia Florou, Andrew Elliott, Matthew H Bailey, et al.NPJ Precision Oncology|March 1, 2026
A first-in-human phase 1 study of the SHP2 inhibitor BBP-398 in patients with advanced solid tumorsGerald Falchook, Camila Braganca Xavier, David Van Veenhuyzen, et al.Journal for Immunotherapy of Cancer|March 15, 2022
Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I studyAung Naing, John D Powderly, John J Nemunaitis, et al.British Journal of Cancer|May 26, 2023
Phase 1 study of GSK3368715, a type I PRMT inhibitor, in patients with advanced solid tumorsAnthony B El-Khoueiry, James Clarke, Tobias Neff, et al.Molecular Cancer Therapeutics|January 11, 2011
PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitorsFilip Janku, Apostolia M Tsimberidou, Ignacio Garrido-Laguna, et al.International Journal of Cancer|January 26, 2019
First-in-human, phase I study of PF-06647263, an anti-EFNA4 calicheamicin antibody-drug conjugate, in patients with advanced solid tumorsIgnacio Garrido-Laguna, Ian Krop, Howard A Burris, et al.Pageof 11